Mabylon raises funding

Mabylon develops monoclonal antibodies, including MY012, which targets the inflammasome pathway. It is leading the Eurostars ASCEND project, worth EUR 1.46 million, to advance this candidate against inflammatory bowel disease.

Announced on
Round
Grant
Amount
Amount not disclosed
Location
canton of Zurich
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic